{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024556","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.952985+00:00","generated_at":"2026-05-16T17:42:42.758564+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025","bullets":["12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.","Phase 3 THIO-104 screening has begun; CEO cites 17.8 months median OS observed in Phase 2 as potential basis for early FDA approval.","A patient treated in March 2023 showed survival of 30 months (912 days) as of September 17, 2025.","Posters presented at SITC 2025 detail Phase 2 and Phase 3 trial designs for ateganosine + cemiplimab in advanced NSCLC.","FDA has granted Fast Track designation for ateganosine in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024556","json":"https://secwatch.observer/filing/0001493152-25-024556.json","markdown":"https://secwatch.observer/filing/0001493152-25-024556.md","text":"https://secwatch.observer/filing/0001493152-25-024556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/0001493152-25-024556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:42:42.758564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}